Citations

Clear

4847 citation(s) found for "Yu, Eric".

Pre- and Postprocedural CT of Transcatheter Left Atrial Appendage Closure Devices
Rajiah, Prabhakar , Thaden, Jeremy J. , Foley, Thomas A. , Williamson, Eric E. , Ranganath, Praveen , Foley, Thomas , Ranganath, Praveen , Rajiah, Prabhakar , Alkhouli, Mohamad

Mayo Clinic

RadioGraphics | May 3, 2021 | Volume: 41 | Issue: 3 | Pages: 680-698

10.1148/rg.2021200136 | PMID 33939541 Get It

527 Patient-Reported Treatment Outcomes in the Mayo Clinic REM Sleep Behavior Disorder Registry: Efficacy of Melatonin and Clonazepam
Grayson, Kammi, Teigen, Luke, Feemster, John, Timm, Paul, Sandness, David J., Junna, Mithri R. , Olson, Eric J. , Tippmann‐Peikert, Maja, Silber, Michael H. , Gossard, Thomas , McCarter, Stuart J. , Carvalho, Diego Z. , Lipford, Melissa C. , Boeve, Bradley F. , Louis, Erik K. St.

Mayo Clinic

Sleep | May 3, 2021 | Volume: 44 | Issue: Supplement_2 | Pages: A207-A208

10.1093/sleep/zsab072.526 Get It

Abstract Introduction REM sleep behavior disorder (RBD) is characterized by disruptive, violent dream enactment behaviors (DEB), necessitating symptomatic treatment to prevent injury and reduce DEB frequency and severity. Melatonin and clonazepam are regarded as RBD therapeutic mainstays, although outcomes data remains limited. We surveyed RBD patients to determine their outcomes following melatonin, clonazepam, and melatonin-clonazepam combination therapy. Methods Mayo Clinic RBD Patient Registry participants received an electronic survey concerning treatment type(s) and dose(s), efficacy, and adverse effects. The primary outcome was treatment efficacy, determined by comparing DEB frequency/severity ratings on a visual analog scale (VAS). Adverse effects severity was assessed by Likert scales. We comparatively analyzed VAS before and after treatment and adverse effects between treatments using non-parametric statistical tests. Results Sixty-eight of 109 patients responded (62.3%; 64 had analyzable data) with a mean age of 67.7 years. Fifty-seven (85%) were men, with mean RBD symptom duration of 13.9 years. Patients receiving each treatment were: melatonin=30, clonazepam=8, and combination=12; 14 received other or no treatment. Baseline VAS ratings were similar between groups. Only melatonin (p=0.003) and combination therapy (p=0.039) improved VAS ratings; clonazepam monotherapy did not improve VAS. Only melatonin monotherapy was reported to lower VAS compared to untreated patients (p=0.02). Optimally effective mean dosages were melatonin 9.95±5.06 mg and clonazepam 0.81±0.48 mg. Patient frequencies reporting one or more moderately-severe side effect(s) were similar between melatonin (15%), clonazepam (7%), and combination therapies (9%). Twenty-five (36.8%) patients had received only one medication trial, while 41.2% required more than one medication. Of these, 15 (22.1%) tried 2 and 13 (19.1%) tried 3 or more treatments. Conclusion Melatonin therapy at an approximate mean 10 mg dosage improved patient-reported DEB frequency/severity on VAS, compared between both previous intraindividual baseline ratings and with untreated patients, while clonazepam monotherapy did not, without differential adverse effects. Clonazepam monotherapy data were limited. These data inform future prospective melatonin symptomatic therapy trials for RBD. Additionally, 41.2% required more than one RBD pharmacological treatment, suggesting a current therapeutic gap and unmet need for future development of biologically-informed, evidence-based symptomatic RBD therapeutics. Support (if any):
Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
Perotti, Paola, Loli, Paola , Decoudier, Bénédicte , Lasolle, Hélène , Dušek, Tina , Bourdeau, Isabelle , Baudin, Éric , Bertherat, Jerome Yves, Terzolo, Massimo , Faßnacht, Martin , Libé, Rossella , Lacroix, André , Kaštelan, Darko , Haak, Harm Reinout , Arlt, Wiebke , Bancos, Irina , Quinkler, Marcus , Fragoso, Maria Candida Barisson Villares , Canu, Letizia , Puglisi, Soraya , Kroiß, Matthias , Berchialla, Paola , Beuschlein, Felix , Berruti, Alfredo

Mayo Clinic

Journal of the Endocrine Society | May 3, 2021 | Volume: 5 | Issue: Supplement_1 | Pages: A166-A167

10.1210/jendso/bvab048.336 Get It

Abstract Background: The ESE-ENSAT guidelines on the management of adrenocortical carcinoma (ACC) suggest adjuvant mitotane for patients at high risk of recurrence following radical surgery. This indication has a limited evidence base, lacking results from randomized controlled trials. No suggestion for or against adjuvant mitotane in low-risk patients was given, since studies did not stratify patients for prognosis. The randomized controlled study ADIUVO compared the efficacy of adjuvant mitotane treatment vs. observation in prolonging recurrence-free survival (RFS) in ACC patients at low-intermediate risk of recurrence. Methods: The main inclusion criteria were: stage I-III ACC, R0 surgery, and Ki-67 ≤10%. Patients were randomly assigned 1:1 to adjuvant mitotane (MIT) or observation (OBS). The primary endpoint of the study was RFS. Patients who refused randomization were offered inclusion in the ADIUVO OBSERVATIONAL study. In this prospective, observational study, patients were managed as in the ADIUVO study. A total of 91 patients were enrolled in ADIUVO, 45 in the MIT and 46 in the OBS arm. Baseline characteristics of patients were perfectly matched between the 2 arms: median age, 51 vs. 50.5 years; female, 73% vs. 67%; stage I, 20% vs. 26%; stage II, 67% vs. 63%, stage III, 13% vs. 11%; ACC secretion 44% vs. 36%; Weiss 5 vs. 5; respectively. In ADIUVO OBSERVATIONAL, 42 patients were treated with mitotane and 53 were untreated. Baseline characteristics of patients were matched between the 2 groups and with MIT and OBS groups in ADIUVO. Thus, the ADIUVO OBSERVATIONAL cohorts could be analyzed in parallel to those of ADIUVO. Results: In the ADIUVO study, recurrences were 8 in the MIT and 11 in the OBS arm, while deaths were 2 and 5, respectively. RFS and overall survival (OS) did not significantly differ between the 2 arms. Tumor size was a predictor of RFS in multivariable analysis. In the OBS arm, the HR for recurrence was 1.321 (95%CI, 0.55–3.32, p=0.54) and HR for death 2.171 (95%CI, 0.52–12.12, p=0.29). The survival analysis in the ADIUVO OBSERVATIONAL study confirmed the findings of ADIUVO. Given the outcome of both studies, the NNT is 55. Conclusions: ACC patients at low-intermediate risk of recurrence after surgery are a minority; however, they show a far better prognosis than expected (5-year RFS is about 75%) and do not benefit significantly from adjuvant mitotane. The results of the ADIUVO study do not support routine use of adjuvant mitotane in this subset of patients, who may thus avoid a potentially toxic treatment. This is an important step toward personalization of ACC care.
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease
Lai, Dongbing , Fontanillas, Pierre , Aasly, Jan , Beecham, Gary W. , Berg, Daniela , Bressman, Susan , Brockmann, Kathrin , Clark, Lorraine N. , Cookson, Mark , Das, Sayantan , Farrer, Matthew J. , Trinh, Joanne , Gasser, Thomas , Gustavsson, Emil K. , Klein, Christine , Langston, J. William, Lynch, Timothy , Marder, Karen, Martin, Eden R. , Mejia‐Santana, Helen, Molho, Eric , Nuytemans, Karen , Ozelius, Laurie J. , Raymond, Deborah , Ross, Owen A. , Samii, Ali, Saunders‐Pullman, Rachel , Schüle, Birgitt , Tolosa, Eduardo , Tomkins, James E. , Vilas, Dolores , Trojanowski, John Q. , Uitti, Ryan J. , Zabetian, Cyrus P. , Urtreger, Avi Orr, Cannon, P. F. , Fiske, Brian , Brockman, Kathrin , Klein, Christine , Ross, Owen A , Uitti, Ryan, Visanji, Naomi P , Zabetian, Cyrus P , Mirelman, Anat , Alipanahi, Babak , Schwantes-An, Tae-Hwi Linus , Alcalay, Roy N. , Brice, Alexis , Deerlin, Vivianna M. Van , Follett, Jordan , Goldwurm, Stefano , Lang, Anthony E. , Latourelle, Jeanne C. , Marras, Connie , McLean, Cory Y. , Myers, Richard H. , Payami, Haydeh , Rogaeva, Ekaterina A. , Rogers, Michael P. , Schulte, Claudia , Scott, William K. , Tanner, Caroline M. , Vance, Jeffery M. , Visanji, Naomi P. , Wszołek, Zbigniew K. , Giladi, Nir , Foroud, Tatiana

Mayo Clinic

Annals of Neurology | May 3, 2021 | Volume: 90 | Issue: 1 | Pages: 76-88

10.1002/ana.26094 | PMID 33938021 Get It

Objective The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age‐at‐onset of Parkinson's disease. Methods We performed the first genomewide association study of penetrance and age‐at‐onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non‐cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age‐at‐onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age‐at‐onset in LRRK2 mutation carriers. Results A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E‐08, beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co‐immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant: p value = 1.1E‐07; age‐at‐onset top variant: p value = 9.3E‐07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age‐at‐onset. Interpretation This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;90:82–94
Mucoepidermoid carcinoma of the parotid gland: Twenty‐year experience in treatment and outcomes
Chan, Stephen A. , Abel, Kathryn M. Van , Lewis, Jean E., Routman, David M. , García, Joaquín J. , Karp, Emily E. , Janus, Jeffrey R. , Kasperbauer, Jan L. , Moore, Eric J. , Van Abel, Kathryn M , Moore, Eric J , Routman, David M , Price, Daniel L.

Mayo Clinic

Head & Neck | May 1, 2021 | Volume: 43 | Issue: 9 | Pages: 2663-2671

10.1002/hed.26735 | PMID 33931913 Get It

AbstractBackgroundParotid gland mucoepidermoid carcinoma (MEC) has published five‐year cancer‐specific survival (CSS) rates of 77%–97%, with variance related to grade.MethodsPatients receiving primary surgery for parotid gland MEC from 1995 to 2014 at a tertiary medical center underwent clinical review, histopathologic review, and cytogenetic analysis. Survival outcomes were evaluated.ResultsAmong 58 patients, T/N/M classification was as follows: T1 in 35 patients, T2 in 14, T4a in 9, N0 in 53, N1 in 2, N2b in 3. Histologic grade was low in 27, intermediate in 17, and high in 12 patients with 98% MAML2 positivity. All patients underwent parotidectomy, and seven patients received adjuvant radiation therapy. CSS was 100% at 5 years and 94.1% at 10 and 15 years. Two patients experienced locoregional recurrence.ConclusionsTreatment with adequate surgical resection and adjuvant radiation therapy for high‐grade or advanced‐stage tumors yields excellent survival, independent of clinical stage or pathologic grade.
Carotid Stenting: Flow Reversal Technique: 2-Dimensional Operative Video
Domingo, Ricardo A. , Ravindran, Krishnan , Tawk, Rabih G. , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , Tawk, Rabih G , Schirmer, Clemens M , Domingo, Ricardo A , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Aziz‐Sultan, Mohammad Ali , Thomas, Ajith J , White, Jonathan Samuel

Mayo Clinic

Operative Neurosurgery | April 30, 2021 | Volume: 21 | Issue: 2 | Pages: E111-E112

10.1093/ons/opab119 | PMID 33929024 Get It

Abstract Management options for carotid stenosis include medical management, carotid endarterectomy, carotid stenting with distal filter protection, or stenting with either flow arrest or flow reversal techniques. 1 Flow reversal with transcarotid artery revascularization (TCAR) technique represents a hybrid approach with surgical access to the common carotid for endovascular placement of a stent in the internal carotid artery. This direct access to the carotid artery avoids navigating the challenging anatomy of the aortic arch with endovascular devices. 2 Compared to transfemoral stenting, TCAR possesses lower risk of transient ischemic attack and stroke, and compared to carotid endarterectomy, there is less risk of cranial neuropathy. 3,4 We present the case of an 87-yr-old man with recurrent severe stenosis (85%) of the right internal carotid artery. The patient had a remote history of bilateral endarterectomies for asymptomatic stenosis and was found with recurrence and progression of right internal carotid artery stenosis. Options were discussed and decision was made to proceed with TCAR after he consented for the procedure. The patient tolerated the procedure well with satisfactory revascularization. Exam remained unremarkable prior to discharge on postoperative day 1 and during follow-up at 1 mo. Patient consented to the publication of their image.
Intracranial Access: Dural Venous Sinus Stenting: 2-Dimensional Operative Video
Domingo, Ricardo A. , Ravindran, Krishnan , Kulakova, Katya, Tawk, Rabih G. , Bain, Mark, Bendock, Bernard, Binning, Mandy J., Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond D , Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Tawk, Rabih G , Schirmer, Clemens M , Domingo, Ricardo A , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | April 23, 2021 | Volume: 21 | Issue: 2 | Pages: E113-E114

10.1093/ons/opab120 | PMID 33891009 Get It

Abstract Cerebral venous sinus stenting has gained popularity in recent years as a safe and efficacious treatment of selected patients with idiopathic intracranial hypertension (IIH) and focal venous sinus stenosis.1–3 - 3 The main goal of treatment is to prevent visual loss, and often patients report resolution of headache and visual symptoms within 21 mo of mean follow-up.4–8 - 8 We present the case of a 57-yr-old woman with medically refractory IIH, bilateral sinus stenosis, and a mass lesion causing stenosis on the left. Venous angiogram with pressure monitoring was completed with the patient awake, which showed a significant pressure gradient on the right (19 mm Hg) and borderline gradient on the left (8 mm Hg). Options were reviewed and decision was made to proceed with the treatment of the right-sided stenosis with stenting and continue with the observation of the lesion on the left to prevent further visual deterioration. The patient consented for the procedure, and she tolerated the procedure well. Neurological exam remained at baseline, and she was discharged home on post-operative day #1. At 2 mo’s follow-up, the patient reported improvement in headaches and remained intact neurologically.
National trends in prescription drug expenditures and projections for 2021
Tichy, Eric M. , Hoffman, James M. , Suda, Katie J. , Rim, Matthew H, Tadrous, Mina , Cuéllar, Sandra , Clark, John Spencer , Wiest, Michelle D., Matusiak, Linda M., Schumock, Glen T.

Mayo Clinic

American Journal of Health-System Pharmacy | April 21, 2021 | Volume: 78 | Issue: 14 | Pages: 1294-1308

10.1093/ajhp/zxab160 | PMID 33880494 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2021 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2021 were reviewed—including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, coronavirus disease 2019 (COVID-19) pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2021 were based on a combination of quantitative analyses and expert opinion. Results In 2020, overall pharmaceutical expenditures in the United States grew 4.9% compared to 2019, for a total of $535.3 billion. Utilization (a 2.9% increase) and new drugs (a 1.8% increase) drove this increase, with price changes having minimal influence (a 0.3% increase). Adalimumab was the top drug in 2020, followed by apixaban and insulin glargine. Drug expenditures were $35.3 billion (a 4.6% decrease) and $98.4 billion (an 8.1% increase) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals the decrease in expenditures was driven by reduced utilization. Several new drugs that will influence spending are expected to be approved in 2021. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2021, we expect overall prescription drug spending to rise by 4% to 6%, whereas in clinics and hospitals we anticipate increases of 7% to 9% and 3% to 5%, respectively, compared to 2020. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib
Rhainds, David , Packard, Chris J. , Brodeur, Mathieu R., Niesor, Eric J. , Sacks, Frank M. , Jukema, J. Wouter , Wright, R. Scott , Waters, David D. , Heinonen, Therèse, Black, Donald M. , Laghrissi‐Thode, Fouzia , Dubé, Marie‐Pierre , Dubé, Marie-Pierre , Wright, R Scott , Pfeffer, Marc Alan , Tardif, Jean‐Claude

Mayo Clinic

Circulation: Genomic and Precision Medicine | April 20, 2021 | Volume: 14 | Issue: 2 | Pages: No page available

10.1161/circgen.121.003219 | PMID 33794646 Get It

Following the neutral results of the dal-OUTCOMES trial, a genome-wide study identified the rs1967309 variant in the adenylate cyclase type 9 ( ADCY9 ) gene on chromosome 16 as being associated with the risk of future cardiovascular events only in subjects taking dalcetrapib, a CETP (cholesterol ester transfer protein) modulator. Homozygotes for the minor A allele (AA) were protected from recurrent cardiovascular events when treated with dalcetrapib, while homozygotes for the major G allele (GG) had increased risk. Here, we present the current state of knowledge regarding the impact of rs1967309 in ADCY9 on clinical observations and biomarkers in dalcetrapib trials and the effects of mouse ADCY9 gene inactivation on cardiovascular physiology. Finally, we present our current model of the interaction between dalcetrapib and ADCY9 gene variants in the arterial wall macrophage, based on the intracellular role of CETP in the transfer of complex lipids from endoplasmic reticulum membranes to lipid droplets. Briefly, the concept is that dalcetrapib would inhibit CETP-mediated transfer of cholesteryl esters, resulting in a progressive inhibition of cholesteryl ester synthesis and free cholesterol accumulation in the endoplasmic reticulum. Reduced ADCY9 activity, by paradoxically leading to higher cyclic AMP levels and in turn increased cellular cholesterol efflux, could impart cardiovascular protection in rs1967309 AA patients. The ongoing dal-GenE trial recruited 6145 patients with the protective AA genotype and will provide a definitive answer to whether dalcetrapib will be protective in this population.
Schistosomiasis prevalence and low-cost diagnostics in rural Northwestern Madagascar: a pilot study
Robinson, Kyle E. , Grewal, Eric P. , Pritt, Bobbi S. , Lloyd, Margaret , Stephano, Adriantiano M., Fardine, Mamantsara, Brumble, Lisa , Pritt, Bobbi S , Grewal, Eric P , Lloyd, Margaret, Libertin, Claudia R.

Mayo Clinic

Journal of Global Health Reports | April 19, 2021 | Volume: 5 | Issue: No issue available | Pages: No page available

10.29392/001c.22123 Get It

Background Schistosomiasis is a parasitic disease that affects the health of hundreds of millions of people worldwide. Affordable diagnostic methods are necessary for developing countries to monitor schistosomiasis rates and treat infected individuals, particularly in, Madagascar, a country with the world’s fifth highest rate of schistosomiasis. Methods We established the prevalence rate of schistosomiasis among the local population served by a clinic in rural northwestern Madagascar. Additionally, we compared different low-cost methods for schistosomiasis detection, including empirical diagnostic methods in use before this study. 500 patients were recruited in this study, of whom 380 received three tests—urine microscopy, point-of-care circulating cathodic antigen (POC-CCA) testing, and urinalysis to screen for Schistosoma haematobium and Schistosoma mansoni. Results By combining these modalities, we recorded a schistosomiasis prevalence rate of 64.47%, which was significantly higher than the 4.84% of patients who were diagnosed and treated through previous empirical methods. Conclusions Our results indicate that screening tests are a necessary component of schistosomiasis control programs. The clinic continued to use urinalysis strip testing and urine microscopy to detect schistosomiasis after this study and decided to discontinue the use of POC-CCA S. mansoni urine testing because of cost. Increased awareness of schistosomiasis resulting from this screening program led to the installation of multiple infrastructure projects in local communities to improve access to potable water, demonstrating community benefits of schistosomiasis screening that extend beyond the identification of infected individuals.